Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907121 | 1.00 | ESR1 (0.32) | ESR1ARESR2TSHR | |
| SCHEMBL1903918 | 1.00 | ESR1 (0.32) | ESR1ARESR2TSHR | |
| SCHEMBL1903171 | 1.00 | ESR1 (0.32) | ESR1ARESR2TSHR | |
| SCHEMBL1903170 | 1.00 | ESR1 (0.32) | ESR1ARESR2TSHR | |
| SCHEMBL12564579 | 1.00 | ESR1 (0.32) | ESR1ARESR2TSHR | |
| SCHEMBL12605623 | 1.00 | ESR1 (0.32) | ESR1ARESR2TSHR | |
| SCHEMBL1907119 | 1.00 | ESR1 (0.32) | ESR1ARESR2TSHR | |
| SCHEMBL21001033 | 0.73 | CA1 (0.33) | — | |
| SCHEMBL21001228 | 0.72 | — | — | |
| SCHEMBL997596 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115304617-A | Synthesis method of oxaspiro diphenol with large steric hindrance and diphosphine ligand thereof | 惠州凯特立斯科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115246767-A | Synthesis method of spiro diphenol with large steric hindrance and diphosphonite compound thereof | 惠州凯特立斯科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20150274705-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-8501977-B2 | Platinum complex and pharmaceutical composition containing the same | UNITECH CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501977-B2 | Platinum complex and pharmaceutical composition containing the same | UNITECH CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501977-B2 | Platinum complex and pharmaceutical composition containing the same | UNITECH CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20110152555-A1 | PLATINUM COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | UNITECH CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152555-A1 | PLATINUM COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | UNITECH CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152555-A1 | PLATINUM COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | UNITECH CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2325163-A1 | PLATINUM COMPLEX AND MEDICAL COMPOUND CONTAINING SAME | Unitech Co., Ltd (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-2325163-A1 | PLATINUM COMPLEX AND MEDICAL COMPOUND CONTAINING SAME | Unitech Co., Ltd (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7732365-B2 | Enantioselective amination and etherification | YALE UNIVERSITY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732365-B2 | Enantioselective amination and etherification | YALE UNIVERSITY (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070259774-A1 | Enantioselective Phosphoramidite Compounds and Catalysts | YALE UNIVERSITY (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259774-A1 | Enantioselective Phosphoramidite Compounds and Catalysts | YALE UNIVERSITY (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274705-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PACSIN2, PRKDC | ESR1 4698/4885AR 3926/4885ESR2 3901/4885 |
| US-20110152555-A1 | PLATINUM COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PKD1, XPA, CCDC47 | ESR1 3744/4885AR 628/4885ESR2 2608/4885 |
| US-20070259774-A1 | Enantioselective Phosphoramidite Compounds and Catalysts | AKR1C3, PCNA, AKR1C4 | ESR1 857/4885AR 150/4885ESR2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.